NCT02581995 - Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. | Biotech Hunter

Enrollment

560

Participants

Timeline

Start Date

November 19, 2015

Primary Completion Date

August 9, 2017

Study Completion Date

August 9, 2017

Conditions

Macular Edema

Interventions

DRUG

Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

2 mg aflibercept administered every 8 weeks following 5 initial monthly doses Intravitreal (IVT) injection

Trial Locations (76)

1083

Budapest

1090

Vienna

1106

Budapest

1133

Budapest

1140

Vienna

1204

Geneva

4032

Debrecen

7621

Pécs

8036

Graz

10122

Turin

13285

Marseille

16132

Genoa

20122

Milan

20132

Milan

35043

Marburg

35128

Padua

37099

Göttingen

46014

Valencia

50134

Florence

50937

Cologne

53105

Bonn

55131

Mainz

60596

Frankfurt am Main

64276

Darmstadt

67063

Ludwigshafen am Rhein

85107

Bratislava

94010

Créteil

B3H 2Y9

Halifax

N6A 4V2

London

L4W 1W9

Mississauga

K1H 8L6

Ottawa

M3C 0G9

Toronto

H4P 2S4

Montreal

J1G 2V4

Sherbrooke

500 05

Hradec Králové

100 34

Prague

401 13

Ústí nad Labem

01067

Dresden

01307

Dresden

04103

Leipzig

00133

Rome

09124

Cagliari

07100

Sassari

LT-50009

Kaunas

LT-08661

Vilnius

85-631

Bydgoszcz

80-809

Gdansk

40-594

Katowice

31-501

Krakow

91-134

Lodz

20-079

Lublin

61-285

Poznan

01-013

Warsaw

04-141

Warsaw

3000-548

Coimbra

2410-197

Leiria

1649-035

Lisbon

4200-319

Porto

2600-178

Vila Franca de Xira

826 06

Bratislava

949 01

Nitra

960 01

Zvolen

01207

Žilina

08907

L'Hospitalet de Llobregat

08190

San Cugat Del Vallès

02006

Albacete

08035

Barcelona

08036

Barcelona

Unknown

Bern

SO16 6YD

Southampton

GU16 7UJ

Camberley

GU2 7XX

Guildford

NE1 4LP

Newcastle upon Tyne

SR2 9HP

Sunderland

LS9 7TF

Leeds

EC1V 2PD

London